Samar Issa

2.4k total citations · 1 hit paper
50 papers, 1.6k citations indexed

About

Samar Issa is a scholar working on Pathology and Forensic Medicine, Genetics and Neurology. According to data from OpenAlex, Samar Issa has authored 50 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pathology and Forensic Medicine, 29 papers in Genetics and 28 papers in Neurology. Recurrent topics in Samar Issa's work include Lymphoma Diagnosis and Treatment (31 papers), CNS Lymphoma Diagnosis and Treatment (28 papers) and Chronic Lymphocytic Leukemia Research (17 papers). Samar Issa is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), CNS Lymphoma Diagnosis and Treatment (28 papers) and Chronic Lymphocytic Leukemia Research (17 papers). Samar Issa collaborates with scholars based in New Zealand, Australia and United States. Samar Issa's co-authors include David Simpson, Peter Wood, David MacDonald, Kathryn S. Kolibaba, Ian W. Flinn, John M. Burke, Tim E. Hawkins, Brad S. Kahl, Doreen M. Hallman and Richard van der Jagt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Samar Issa

49 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

2014 419 citations Ian W. Flinn, Richard van der Jagt et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samar Issa New Zealand	15	1.3k	926	725	662	146	50	1.6k
Mars van’t Veer Netherlands	7	586 0.5×	448 0.5×	409 0.6×	302 0.5×	87 0.6×	8	1.0k
Graham W. Slack Canada	24	1.7k 1.3×	660 0.7×	571 0.8×	1.1k 1.7×	278 1.9×	97	2.2k
Monica Balzarotti Italy	23	1.2k 0.9×	402 0.4×	545 0.8×	699 1.1×	365 2.5×	69	1.5k
Ulrich von Grünhagen Germany	6	1.2k 1.0×	789 0.9×	197 0.3×	849 1.3×	129 0.9×	10	1.4k
J. Matthews United Kingdom	13	988 0.8×	428 0.5×	158 0.2×	664 1.0×	126 0.9×	20	1.1k
Alice Di Rocco Italy	16	775 0.6×	270 0.3×	317 0.4×	466 0.7×	135 0.9×	64	1.1k
Charles Foussard France	12	885 0.7×	356 0.4×	195 0.3×	601 0.9×	59 0.4×	22	1.0k
Elisabeth Wassner-Fritsch Switzerland	12	1.1k 0.9×	768 0.8×	124 0.2×	743 1.1×	69 0.5×	20	1.3k
W. Hiddemann Germany	2	871 0.7×	432 0.5×	140 0.2×	627 0.9×	62 0.4×	2	969
Robin Weaver United States	6	800 0.6×	460 0.5×	107 0.1×	535 0.8×	68 0.5×	6	1.2k

Countries citing papers authored by Samar Issa

Since Specialization

Citations

This map shows the geographic impact of Samar Issa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samar Issa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samar Issa more than expected).

Fields of papers citing papers by Samar Issa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samar Issa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samar Issa. The network helps show where Samar Issa may publish in the future.

Co-authorship network of co-authors of Samar Issa

This figure shows the co-authorship network connecting the top 25 collaborators of Samar Issa. A scholar is included among the top collaborators of Samar Issa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samar Issa. Samar Issa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruskova, Anna, Christin Coomarasamy, Leanne Berkahn, et al.. (2023). Diffuse large B‐cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high‐dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis. American Journal of Hematology. 98(7). 1070–1079. 5 indexed citations

Bromberg, Jacoline E. C., Samar Issa, Bronno van der Holt, et al.. (2023). Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study. Neuro-Oncology. 26(4). 724–734. 5 indexed citations

Meulen, Matthijs van der, Renske Gahrmann, Bronno van der Holt, et al.. (2023). P20.11.A TEMPORAL MUSCLE THICKNESS AS PROGNOSTIC MARKER IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA - A VALIDATION STUDY. Neuro-Oncology. 25(Supplement_2). ii129–ii129. 1 indexed citations

Meulen, Matthijs van der, Linda Dirven, Esther J. J. Habets, et al.. (2021). Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. Neuro-Oncology. 23(8). 1315–1326. 9 indexed citations

Meulen, Matthijs van der, Linda Dirven, Katerina Bakunina, et al.. (2021). MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. Journal of Neuro-Oncology. 152(2). 357–362. 14 indexed citations

Meulen, Matthijs van der, Katerina Bakunina, Marcel Nijland, et al.. (2020). Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. Annals of Oncology. 31(8). 1046–1055. 4 indexed citations

Issa, Samar, et al.. (2019). Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature. Journal of Clinical Neuroscience. 71. 277–280. 1 indexed citations

Schmitt, Andreas M., Amanda K. Herbrand, Christopher P. Fox, et al.. (2019). Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis. Hematological Oncology. 37(5). 548–557. 51 indexed citations

Kahl, Brad S., John M. Burke, Richard van der Jagt, et al.. (2017). Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial. Blood. 130. 484–484. 10 indexed citations

10.

Chan, Henry, et al.. (2016). Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients. Leukemia & lymphoma. 57(11). 2584–2592. 7 indexed citations

11.

Burke, John M., Brad S. Kahl, Peter Wood, et al.. (2016). Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 16(4). 182–190.e1. 14 indexed citations

12.

Flinn, Ian W., Richard van der Jagt, Brad S. Kahl, et al.. (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123(19). 2944–2952. 419 indexed citations breakdown →

13.

Jackson, Sharon, et al.. (2013). Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and a Trend Towards Improved Survival In Obese Patients. Blood. 122(21). 4343–4343. 1 indexed citations

14.

McQueen, Fiona & Samar Issa. (2013). Is rheumatoid arthritis a B-cell haematological disease with a predilection for the joints? Following the B cell thread to its logical conclusion. Medical Hypotheses. 82(3). 266–270. 3 indexed citations

15.

Wieduwilt, Matthew J., Francisco Valles, Samar Issa, et al.. (2012). Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI. Clinical Cancer Research. 18(4). 1146–1155. 99 indexed citations

16.

Lee, Sophie, et al.. (2012). Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost–benefit and quality of life analysis. Supportive Care in Cancer. 21(3). 841–846. 18 indexed citations

17.

Bromberg, Jacoline E. C., Jeanette K. Doorduijn, Gerald Illerhaus, et al.. (2012). Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project. Haematologica. 98(5). 808–813. 43 indexed citations

18.

Burke, John M., Richard H. van der Jagt, Brad S. Kahl, et al.. (2012). Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma. Blood. 120(21). 155–155. 5 indexed citations

19.

Rubenstein, James L., Jane Fridlyand, Lauren E. Abrey, et al.. (2007). Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma. Journal of Clinical Oncology. 25(11). 1350–1356. 243 indexed citations

20.

Issa, Samar, Arthur Shen, Jon Karch, et al.. (2007). Treatment of Primary CNS Lymphoma with Induction High-Dose Methotrexate, Temozolomide, Rituximab Followed by Consolidation Cytarabine/Etoposide: A Pilot Study with Biomarker Analysis.. Blood. 110(11). 1364–1364. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact